Faeth Therapeutics, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Faeth Therapeutics reported Q3 2026 cash and equivalents of $174.8M (vs. $21.2M at end-2025), a net increase of $153.6M, reflecting a major capital raise. The company's lead program PIKTOR (serabelisib + sapanisertib) received FDA Fast Track designation for advanced endometrial cancer and is on track to report Phase 2 PIK-201 topline data by year-end 2026. R&D expenses increased to $11.7M (Q3 2026) from $2.5M (Q3 2025); net loss was $20.4M ($0.79/share) on 25.8M weighted-average shares outstanding.
Why this rating
Major capital infusion (~22× company market cap) extends runway materially; Fast Track designation accelerates regulatory path. For a $7.1M-cap biotech, this funding is transformational. Near-term catalyst risk if Phase 2 misses.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.